Member Info for BBB11

I stand corrected. G Rex process is 12 days.

I believe G rex isn't in place for phase 1? Agreed it's game changer but it is not currently implemented to my knowledge?

Simple AI answer

The current HG-CT-1 manufacturing timeline is likely in the standard autologous CAR-T range of roughly 4–6 weeks from leukapheresis to infusion — collection, activation, gene insertion, expansion, quality testing, shipping, then lymphodepleting chemo before infusion. Hemogenyx hasn't published a specific day-by-day breakdown in any RNS.

Made Scientific improves capacity, consistency, and scalability with professional GMP facilities — but it doesn't fundamentally shorten the manufacturing duration itself. The real step change in speed would come from the Kure.ai ultrafast manufacturing partnership (sub-72 hour process), but that's not being used in the current Phase 1 trial.

Caveats:

No official Hemogenyx-specific timeline has been published via RNS

4–6 weeks is based on standard industry autologous CAR-T norms

Made reduces production risk and slot delays, not the core manufacturing clock

Kure.ai ultrafast manufacturing is a future development track, not current trial protocol

Lymphodepleting chemo scheduling adds further time beyond manufacturing itself

ASAP.

This has been confirmed directly by Vlad via email correspondence. There is no wait required.

Alde -

You’re right that Phase 1 is about safety, but you’re misunderstanding HG-CT-1’s clinical goal.

Nobody is claiming the lowest dose is a standalone "miracle cure." Its actual purpose is to act as a stepping stone, stabilizing R/R AML patients to bridge them to a curative bone marrow transplant. If Cohort 1 patients are surviving past the usual 4 to 6 months, the drug is doing exactly what it was designed to do.

As for CDX and CBR, the lack of news is frustrating, but the company's capital and focus have to be on executing the active Phase 1 trial right now, which the tech transfer news proves they are doing. JV is definitely on the table for them to progress.

Alde that's because he needs to have time to create a JV for them. Which a few of us think he is in discussions on.

I think this will rise now.

While the Company's efforts remain primarily focused on the HG-CT-1 clinical trials, it continues to advance its CDX and CBR product candidates where possible and expects to report further progress on these programmes in due course.

Next RNS:

CDX/CBR to get a JV 🤞

Estonia now wide open to be approved.

First adult for Cohort 2 and child recruitment for pediatric cohort 1.

Adult cohort 1 update.

FY2025 Annual Report drop (financials, runway, and CEO narrative).

Kure.ai collaboration progress on ultrafast manufacturing.

Potential FDA Orphan Drug Designation (ODD) application/approval.

Warrant exercise news to secure the trial runway.

Alde, now the time to buy surely?

Major de-risking event... Completed.

Alder - That is a massive leap to assume the worst just because there isn't a dedicated PR update. If there had been a fatal, drug-related event, the DSMB would have halted the trial, but there is currently no trial pause or safety hold. The DSMB already cleared the dose escalation back in October 2025 after reviewing all three patients.

There is absolutely no regulatory obligation to release day-to-day survival updates unless it triggers a material change. It is standard industry practice to hold this kind of data so it can be packaged alongside the next major milestone, like Cohort 2 progress. Furthermore, the real question you should be asking is: did the patients survive past the usual 4 to 6 month median survival time for R/R AML? If so, then we can start assuming some level of efficacy.

Silence here just means they are waiting to present a complete dataset, not that they are hiding bad news. The data will likely come with a formal Cohort 1 progression update. While confirming 1-year survival would be huge for shareholder sentiment, dropping isolated individual patient data outside of a full cohort readout is frowned upon in the clinical sector... As I learned when I was hoping for an update on this exact thing.

Jump in the ask to £10.40

Some very nice buys coming through! RNS tomorrow?

Hargreaves Lanadown all is down this morning. Which is the majority platform of Hemo stock. So noone can buy until they called or got on a laptop. Was the perfect storm that the sells were constant and noone could really buy.

Yup. My bad. It's 5.30pm today in California. My RSS feed for Hemo plugged into Gemini for some reason made that all on its own. Sorry all

Dr. Vladislav Sandler, the CEO of Hemogenyx Pharmaceuticals, presented today, March 19, 2026, at the H.C. Wainwright Global Investment Conference.

The talk served as a strategic update for investors and clinical partners, focusing on the company’s transition from a pre-clinical to a clinical-stage biotech firm.

Key Highlights of the Talk

HG-CT-1 Progress: Vlad provided a significant update on the HEMO-CAR-T program. He confirmed that the Phase I clinical trial for relapsed/refractory Acute Myeloid Leukemia (AML) is advancing well, specifically mentioning the move into higher dose cohorts following positive safety data from initial patients.

Pediatric Expansion: A major point of the talk was the inclusion of pediatric patients. Following recent regulatory clearances, the trial is now recruiting patients aged 12–18, which significantly expands the potential impact of their CAR-T therapy.

The CBR Platform: He detailed the Chimeric Bait Receptor (CBR) platform, describing it as a "next-generation" immunotherapy. Unlike traditional CAR-T, this platform aims to reprogram innate immune cells to fight not only cancers but also viral infections, positioning Hemogenyx within the biodefense sector.

Near-Term Revenue Strategy: Vlad discussed the company’s unique approach to early commercialization, specifically mentioning the Estonian hospital exemption law. This pathway could allow the company to generate revenue from their CAR-T therapy via government reimbursement before full global regulatory approval is finalized.

Manufacturing Partnerships: He highlighted recent technology transfers and partnerships designed to scale up "one-day manufacturing," which aims to reduce the time and cost of delivering cell therapies to patients.

Note: Dr. Sandler emphasized that these developments aim to make bone marrow transplantation—traditionally a "last resort" treatment—safer and more accessible for patients with blood and autoimmune diseases.

the uk’s largest data centre scheme being built near s****horpe for £7.5b. i wonder if he's won that contract and putting the spoils into hemo haha!

blue day, even with mostly sells, hidden buys to be released tomorrow?

If you hold that much outside of a multi year built stocks and shares ISA or SIPP then that sounds like a mighty tax bill. One of the reasons I hate crypto is having to send that to my accountant each year for my self assessment. Although there was no capital gains on that this year... FML.

Let's see a frenzy of Hemo buys now!

I came here to say, I am just waiting for someone to say there's been a leak 🤣. Never disappoint do you Pumpky